Calidi Biotherapeutics, INC 8-K filings

Calidi Biotherapeutics announced positive FDA feedback for CLD-401, advanced its RedTail platform with new data, and reduced G&A expenses in its Q2 2026 report.

Calidi Biotherapeutics announced a 1-for-16 reverse stock split, effective July 30, 2026, to increase its share price and maintain NYSE American listing.

Calidi Biotherapeutics has entered into a new lease agreement for office and laboratory space, anticipating significant annual cost reductions.

Calidi Biotherapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all presented proposals, including director election, auditor ratification, a reverse stock split, and a plan amendment, were approved.

Calidi Biotherapeutics has amended a previously issued warrant to include stockholder approval requirements and adjust vesting terms.

Calidi Biotherapeutics announced first quarter 2026 financial results, highlighting progress in its CLD-401 and RedTail platform development, alongside a significant reduction in administrative expenses.

Calidi Biotherapeutics has issued a warrant to an accredited investor for up to 17,391,304 shares, contingent on future stock purchases.

Calidi Biotherapeutics announced changes to its Board of Directors, including the departure of Allan J. Camaisa and the appointment of Scott Leftwich to the Audit Committee.

Calidi Biotherapeutics reported Q4 and full-year 2025 financial results, highlighting progress in its CLD-401 clinical program and recent capital raises.

Calidi Biotherapeutics announced its third quarter 2025 financial results and highlighted progress in its RedTail platform and CLD-401 development, alongside a successful $6.9 million public offering.

Calidi Biotherapeutics presented new preclinical data on its lead therapeutic candidate, CLD-401, at the 2025 SITC Annual Meeting, highlighting its RedTail platform's ability to target metastatic tumors.

Calidi Biotherapeutics, Inc. has sold its 75% equity interest in subsidiary Nova Cell, Inc. for $6 million, aiming for $0.5 million in annual G&A expense reductions.

Calidi Biotherapeutics announced the formation of a Scientific Advisory Board to guide the development of its RedTail platform and advance CLD-401 into clinical trials.

Calidi Biotherapeutics, Inc. announced the elimination of its Chief Legal Officer position and the termination of Ms. Wendy Pizarro Campbell's employment, effective October 17, 2025, as part of cost-reduction initiatives.

Calidi Biotherapeutics, Inc. released an updated investor presentation on its website, furnished as Exhibit 99.1 to a Form 8-K.

Calidi Biotherapeutics successfully closed a $6.9 million underwritten public offering, including the full exercise of the underwriters' over-allotment option, to fund working capital and clinical trials.

Calidi Biotherapeutics, Inc. announced the finalization of a separation agreement with former President, Medical and Scientific Affairs, Dr. Boris Minev, including a $100,000 bonus and $187,500 severance.

Calidi Biotherapeutics announced reduced net loss in Q2 2025, alongside key clinical advancements and a successful capital raise.

Calidi Biotherapeutics, Inc. completed a 1-for-12 reverse stock split to optimize market dynamics and broaden investor appeal, effective August 4, 2025.

Calidi Biotherapeutics, Inc. will implement a 1-for-12 reverse stock split to enhance market appeal and has eliminated the President, Medical and Scientific Affairs position as part of cost optimization.

Calidi Biotherapeutics, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the election of two Class II Directors, ratification of its auditor, authorization for a reverse stock split, and an increase in shares for its 2023 Equity Incentive Plan.

Calidi Biotherapeutics has entered into an agreement with seven warrant holders to immediately exercise existing warrants at a reduced price, generating approximately $4.6 million in gross proceeds, and will issue new Series H warrants as an inducement.

Calidi Biotherapeutics announced its Q1 2025 financial results, highlighting key operational advancements including the selection of an IL15-superagonist payload for its Redtail platform and FDA clearance for its CLD-201 clinical trial.

Calidi Biotherapeutics replaces its independent auditor from Marcum LLP to CBIZ CPAs P.C. following CBIZ's acquisition of Marcum's attest business.

Calidi Biotherapeutics appoints Eric Poma as CEO and Director, succeeding Allan Camaisa who will remain on the Board, effective April 22, 2025.

Calidi Biotherapeutics appoints Guy Travis Clifton, MD, as Chief Medical Officer, Consultant, and Advisor, effective April 8, 2025.

Calidi Biotherapeutics closes a $3.9 million registered direct offering and concurrent private placement to fund working capital and advance clinical programs.

Calidi Biotherapeutics announced its fourth quarter and full-year 2024 financial results, highlighting progress in its clinical programs and a reduction in net losses.

Calidi Biotherapeutics reports successful delivery of transient gene therapy payloads to tumors using its systemic RTNova platform, along with efficacy in killing over 60 tumor cell lines.

Calidi Biotherapeutics amends its previous Form 8-K filing to include the consent of its independent registered public accounting firm, Marcum LLP.